A major announcement at the American Society of Clinical Oncology annual meeting: The drug exemestane significantly reduces the risk of breast cancer in high-risk, postmenopausal women. It is the result of an international, randomized double-blind phase III clinical trial in which University at Buffalo researchers and hundreds of Western New York women played a critical role...
More...
Threaded Mode